Do you want to read an article? Please log in or register.
Serum IgG subclass levels and risk of exacerbations and hospitalizations in patients with COPD
COPD
Related content
COPD
Serum CCL-18 level is a risk factor for COPD exacerbations requiring hospitalization.
Int J Chron Obstruct Pulmon Dis.
Dilektasli AG, Demirdogen Cetinoglu E, Uzaslan E, Budak F, Coskun F, Ursavas A, Ercan I, Ege E
doi: 10.2147/COPD.S118424.
RECOMMENDED
COPD
Serum IgG Levels and Risk of COPD Hospitalization: A Pooled Meta-Analysis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Chest.
Leitao Filho FS, Mattman A, Schellenberg R, Criner GJ, Woodruff P, Lazarus SC, Albert RK, Connett J, Han MK, Gay SE, Martinez FJ, Fuhlbrigge AL, Stoller JK, MacIntyre NR, Casaburi R, Diaz P, Panos RJ, Cooper JA Jr, Bailey WC, LaFon DC, Sciurba FC, Kanner RE, Yusen RD, Au DH, Pike KC, Fan VS, Leung JM, Man SP, Aaron SD, Reed RM, Sin DD
doi: 10.1016/j.chest.2020.04.058.
COPD
Characteristics and risk factors for inconsistency between the risk of exacerbations and the severity of airflow limitation in COPD based on GOLD 2017: A retrospective, cross-sectional study
PLoS One.
Huang WC, Wu MF, Chen HC, Hsu JY
doi: 10.1371/
RECOMMENDED
COPD
Clinical variables predicting the risk of a hospital stay for longer than 7 days in patients with severe acute exacerbations of chronic obstructive pulmonary disease: a prospective study
Respir Res.
Crisafulli E, Ielpo A, Barbeta E, Ceccato A, Huerta A, Gabarrús A, Soler N, Chetta A, Torres A
doi: 10.1186/s12931-018-0951-4.
RECOMMENDED
COPDPneumonia
Roflumilast in Severely Ill Patients with Chronic Obstructive Pulmonary Disease with Frequent Exacerbations: Risk of Pneumonia Hospitalization and Severe Exacerbations
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
J Clin Med.
Alispahic IA, Sørensen R, Eklöf J, Sivapalan P, Løkke A, Seersholm N, Vestergaard JH, Jensen JS
doi: 10.3390/jcm9051442.
COPD
Treatment with long acting muscarinic antagonists stimulates serum levels of irisin in patients with COPD
Pulm Pharmacol Ther.
Mandal J, Roth M, Papakonstantinou E, Sun Q, Costa L, Boeck L, Scherr A, Rakic J, Louis R, Milenkovic B, Boersma W, Kostikas K, Blasi F, Aerts J, Rohde G, Lacoma A, Torres A, Welte T, Tamm M, Stolz D
doi: 10.1016/j.pupt.2017.10.011.
RECOMMENDED
COPD
Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation: A Randomized Clinical Trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
JAMA
Jiménez D, Agustí A, Tabernero E, Jara-Palomares L, Hernando A, Ruiz-Artacho P, Pérez-Peñate G, Rivas-Guerrero A, Rodríguez-Nieto MJ, Ballaz A, Agüero R, Jiménez S, Calle-Rubio M, López-Reyes R, Marcos-Rodríguez P, Barrios D, Rodríguez C, Muriel A, Bertoletti L, Couturaud F, Huisman M, Lobo JL, Yusen RD, Bikdeli B, Monreal M, Otero R, SLICE Trial Group.
doi: 10.1001/jama.2021.14846
COPD
The predictive value of an adjusted COPD assessment test score on the risk of respiratory-related hospitalizations in severe COPD patients
Chron Respir Dis.
Sloots JM, Barton CA, Buckman J, Bassett KL, Palen JV, Frith PA, Effing TW
doi: 10.1177/1479972316687099.
RECOMMENDED
COPD
Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial
JAMA.
Wise RA, Chapman KR, Scirica BM, Bhatt DL, Daoud SZ, Zetterstrand S, Reisner C, Gil EG
doi: 10.1001/jama.2019.4973.